---
document_datetime: 2023-09-21 19:13:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ultratard-epar-all-authorised-presentations_en.pdf
document_name: ultratard-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9737685
conversion_datetime: 2025-12-21 19:49:31.484002
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number       | Invented name   | Strength   | Pharmaceutical form      | Route of administration   | Packaging    | Content (concentration)   | Package size   |
|-----------------|-----------------|------------|--------------------------|---------------------------|--------------|---------------------------|----------------|
| EU/1/02/236/001 | Ultratard       | 40 IU/ml   | Suspension for injection | Subcutaneous use          | Vial (glass) | 10ml (1.4 mg/ml)          | 1 vial         |
| EU/1/02/236/002 | Ultratard       | 40 IU/ml   | Suspension for injection | Subcutaneous use          | Vial (glass) | 10 ml (1.4 mg/ml)         | 5 vials        |
| EU/1/02/236/003 | Ultratard       | 100 IU/ml  | Suspension for injection | Subcutaneous use          | Vial (glass) | 10ml (3.5 mg/ml)          | 1 vial         |
| EU/1/02/236/004 | Ultratard       | 100 IU/ml  | Suspension for injection | Subcutaneous use          | Vial (glass) | 10 ml (3.5 mg/ml)         | 5 vials        |

Medicinal Product no longer authorised